Overview

Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer

Status:
RECRUITING
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of BGT007H cell therapy in patients with recurrent/refractory pancreatic cancer.
Phase:
NA
Details
Lead Sponsor:
RenJi Hospital